Table 2. Meta-analysis of association between MMPs polymorphism and ovarian cancer.
| comparison model | OR(95%CI) | PORa | I2 | Phetb |
|---|---|---|---|---|
| MMP1 rs1799750 | ||||
| 1G1G vs 2G2G | 0.93(0.70–1.23) | 0.60 | 0% | 0.50 |
| 1G2G vs 2G2G | 1.09(0.78–1.54) | 0.61 | 53% | 0.08 |
| 1G1G+1G2G vs 2G2G | 1.02(0.83–1.25) | 0.84 | 24% | 0.26 |
| 1G1G vs 1G2G+2G2G | 0.95(0.75–1.21) | 0.67 | 20% | 0.29 |
| 1G vs 2G | 1.00(0.85–1.17) | 0.99 | 44% | 0.13 |
| MMP3 rs34093618 | ||||
| 5A5A vs 6A6A | 1.25(0.70–2.24) | 0.46 | 0 | 0.98 |
| 5A6A vs 6A6A | 1.08(0.51–2.31) | 0.84 | 69 | 0.04 |
| 5A5A+5A6A vs 6A6A | 0.97(0.68–1.38) | 0.85 | 53 | 0.12 |
| 5A5A vs 5A6A+6A6A | 1.12(0.69–1.80) | 0.65 | 43 | 0.17 |
| 5A vs 6A | 1.01(0.79–1.31) | 0.91 | 0 | 0.49 |
a P value of the Z-test for odds ratio test
b P value of the Q-test for heterogeneity test.